Rare but serious risks, such as pancreatitis, must also be considered
The rate varies significantly between individuals, but a general pattern emerges
The Three-Receptor Approach Retatrutide belongs to a class called triple-agonist medications
Retatrutide (LY3437943) is an investigational compound studied in clinical trials and is not FDA-approved for general use
Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor
Methods Data were obtained via an online survey of 10,076 adults in Canada with diverse SDOH
